NeuroMetrix, Inc. (NURO) News
Filter NURO News Items
NURO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NURO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NURO News From Around the Web
Below are the latest news stories about NEUROMETRIX INC that investors may wish to consider to help them evaluate NURO as an investment opportunity.
Here’s Why NeuroMetrix, Inc. (NASDAQ:NURO) Is Among the Best Diabetes Stocks to Buy Under $10We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where NeuroMetrix, Inc. (NASDAQ:NURO) stands against the other diabetes stocks. Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration About 422 million people […] |
NeuroMetrix to be Acquired by electroCoreNeuroMetrix shareholders to receive cash and Contingent Value RightsWOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, will acquire NeuroMetrix. The transaction has been unanimously approved by the Boards of Directors of both companies and is expec |
NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives GrowthDespite a 51% revenue dip, NURO narrowed losses in Q3 2024 by reducing operating expenses by 25%, offsetting the challenging revenue environment. |
NeuroMetrix Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023)NeuroMetrix ( NASDAQ:NURO ) Third Quarter 2024 Results Key Financial Results Revenue: US$587.3k (down 51% from 3Q... |
NeuroMetrix Reports Q3 2024 Business HighlightsCompany Continues to Pursue Review of Strategic AlternativesWOBURN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine months ended September 30, 2024. The Company develops proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. NeuroMetrix, Inc. is actively pursuing its previously announced review of strategic options to enhance shareholder value. |
NeuroMetrix Reiterates its Review of Strategic AlternativesWOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past 6 months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, oper |
NeuroMetrix Second Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)NeuroMetrix ( NASDAQ:NURO ) Second Quarter 2024 Results Key Financial Results Revenue: US$769.1k (down 54% from 2Q... |
NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic OptionsWOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, t |
NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference CallWOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and uniqu |
NeuroMetrix Reports Q1 2024 Business HighlightsWOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. “We are focused on maximizing shareholder value,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “Shareholders have recently provided valuable insights in addition t |